Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 4/20 | 0.49 |
| ▸ | NOS3 | P29474 | 3/20 | 0.49 |
| ▸ | NOS2 | P35228 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | THPO | P40225 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | KMO | O15229 | 1/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | OGT | O15294 | 1/20 | 0.37 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.37 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28877994 | 0.79 | PSMB8 (0.55) | LMNAMEN1KMT2APSMB8GAA | |
| SCHEMBL488612 | 0.78 | AURKA (0.49) | NOS1NOS3NOS2LMNACYP1A2 | |
| SCHEMBL3588183 | 0.78 | PDE3B (0.39) | NOS1NOS3NOS2LMNACYP1A2 | |
| SCHEMBL12232243 | 0.78 | NOS1 (0.49) | NOS1NOS3NOS2KMOPDE3B | |
| SCHEMBL28669342 | 0.74 | CREBBP (0.41) | LMNAPDE3BPDE3AMEN1KMT2A | |
| SCHEMBL17429248 | 0.74 | PDE3B (0.39) | NOS1NOS3NOS2LMNACYP1A2 | |
| SCHEMBL11916127 | 0.74 | PDE3B (0.39) | NOS1NOS3NOS2LMNACYP1A2 | |
| SCHEMBL28522475 | 0.74 | PDE3B (0.36) | NOS1NOS3NOS2LMNACYP1A2 | |
| SCHEMBL8627144 | 0.73 | CREBBP (0.43) | NOS1NOS3NOS2KMOLRRK2 | |
| SCHEMBL3213407 | 0.73 | PSMB8 (0.39) | PDE3BPDE3AMEN1KMT2APSMB8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11767296-B2 | Heteroaryl compounds as kinase inhibitor | FUJIAN HAIXI PHARMACEUTICALS CO., LTD (CN) | 2023-09-26 | — | — | US | disclosed |
| US-11767296-B2 | Heteroaryl compounds as kinase inhibitor | FUJIAN HAIXI PHARMACEUTICALS CO., LTD (CN) | 2023-09-26 | — | — | US | disclosed |
| US-11767296-B2 | Heteroaryl compounds as kinase inhibitor | FUJIAN HAIXI PHARMACEUTICALS CO., LTD (CN) | 2023-09-26 | — | — | US | disclosed |
| CN-116715625-A | Heteroaryl compounds as protein kinase inhibitors | 福建海西新药创制股份有限公司 | 2023-09-08 | — | — | CN | disclosed |
| CN-111601790-B | Heteroaryl compounds as protein kinase inhibitors | 福建海西新药创制股份有限公司 | 2023-03-31 | — | — | CN | disclosed |
| US-20220380312-A1 | HETEROARYL COMPOUNDS AS KINASE INHIBITOR | FUJIAN HAIXI PHARMACEUTICALS CO., LTD (CN) | 2022-12-01 | — | — | US | disclosed |
| CN-110950888-B | Preparation method of chlorooxanone with Vilsmeier reagent | 山东省科学院菏泽分院 | 2022-05-20 | — | — | CN | disclosed |
| EP-3749646-B1 | HETEROARYL COMPOUNDS AS KINASE INHIBITOR | FUJIAN HAIXI PHARMACEUTICALS CO LTD (CN) | 2022-04-06 | — | — | EP | disclosed |
| CN-111601790-A | Heteroaryl compounds as protein kinase inhibitors | 福建海西新药创制有限公司 | 2020-08-28 | — | — | CN | disclosed |
| CN-110950888-A | Preparation method of chlorooxanone with Vilsmeier reagent | 山东省科学院菏泽分院 | 2020-04-03 | — | — | CN | disclosed |
| EP-1931348-A2 | MONOCYCLIC AND BICYCLIC COMPOUNDS AND METHODS OF USE | ChemoCentryx Inc (US) | 2008-06-18 | — | — | EP | disclosed |
| US-20070254886-A1 | Chemokine Receptor Antagonist and Medical Use Thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-11-01 | — | — | US | disclosed |
| US-20070066583-A1 | Monocyclic and bicyclic compounds and methods of use | CHEMOCENTRYX, INC. (US) | 2007-03-22 | — | — | US | disclosed |
| US-20070066583-A1 | Monocyclic and bicyclic compounds and methods of use | CHEMOCENTRYX, INC. (US) | 2007-03-22 | — | — | US | disclosed |
| US-20070066583-A1 | Monocyclic and bicyclic compounds and methods of use | CHEMOCENTRYX, INC. (US) | 2007-03-22 | — | — | US | disclosed |
| WO-2007022257-A2 | MONOCYCLIC AND BICYCLIC COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX, INC. (US) | 2007-02-22 | — | — | WO | disclosed |
| WO-2007022257-A2 | MONOCYCLIC AND BICYCLIC COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX, INC. (US) | 2007-02-22 | — | — | WO | disclosed |
| EP-1661889-A1 | CHEMOKINE RECEPTOR ANTAGONIST AND MEDICAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-05-31 | — | — | EP | disclosed |
| US-4192946-A | Process for producing 3-hydroxy-5-halopyridines | CIBA-GEIGY CORPORATION (US) | 1980-03-11 | — | — | US | disclosed |
| US-4033975-A | Process for the production of 2-amino-3-hydroxypyridine derivatives | CIBA-GEIGY CORPORATION (US) | 1977-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11767296-B2 | Heteroaryl compounds as kinase inhibitor | RET, ERBB2, ABL1 | NOS1 4499/4885NOS3 4250/4885NOS2 4593/4885 |
| US-20220380312-A1 | HETEROARYL COMPOUNDS AS KINASE INHIBITOR | RET, ERBB2, ABL1 | NOS1 4499/4885NOS3 4250/4885NOS2 4593/4885 |
| US-20070066583-A1 | Monocyclic and bicyclic compounds and methods of use | CCR1, CCR3, CCR4 | NOS1 4000/4885NOS3 4240/4885NOS2 4595/4885 |
| US-20070254886-A1 | Chemokine Receptor Antagonist and Medical Use Thereof | CCR5, CCR4, CCR1 | NOS1 904/4885NOS3 784/4885NOS2 965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.